JP Morgan upgraded Smith & Nephew from Neutral to Overweight
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2025 | Buy → Hold | HSBC Securities | |
| 3/12/2025 | Buy → Neutral | UBS | |
| 11/6/2024 | Buy → Hold | Berenberg | |
| 11/1/2024 | Buy → Hold | Deutsche Bank | |
| 7/24/2024 | Buy | Deutsche Bank | |
| 6/5/2024 | Neutral → Buy | UBS | |
| 11/28/2023 | Underweight → Equal Weight | Barclays | |
| 11/3/2023 | Neutral → Overweight | JP Morgan |
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle. Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices*, the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, inclu
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of ‘Life Unlimited' - making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint re
The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-ce
HSBC Securities downgraded Smith & Nephew from Buy to Hold
UBS downgraded Smith & Nephew from Buy to Neutral
Berenberg downgraded Smith & Nephew from Buy to Hold
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
3 - SMITH & NEPHEW PLC (0000845982) (Reporting)
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy
STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors. Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM. He recent
New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc
New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra
Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an
SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)
SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)